Stock info Enzo Biochem | Filter  Basic-Info

Enzo Biochem

The past year was a relatively good year for Enzo Biochem investors

The stock gained over the past 12 months at around 45 percent. Over the past 5 years Enzo Biochem' stock rose at around 243 percent in value. Enzo Biochem's revenues between 2011 and 2015 were very constant and moved between 103,08 million dollars and 97,6 million dollars. The net results between 2011 and 2015 were far from constant and fluctuated between -12,96 million dollars and -2,29 million dollars.

Enzo Biochem mainly operates in the biotech sector. Over the past 10 years the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

Over the past 5 years the American company paid out dividends.

Enzo Biochem financed with a quite low debt position

At the end of 2015 the biotech company's balance sheet was worth 68,39 million dollars. At the end of 2015 the total debt positon equaled 25,78 million dollars. This is around 37,7 percent of the total balance sheet. As per the end of 2015 Enzo Biochem's price/earnings-ratio equaled -49. So investors paid for 1 stock -49 times the earnings per share of 2015. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.

At the end of 2015 the American company's market capitalization equaled around 204,1 million dollars. At the end of 2015 the American company had around 45,36 million stocks listed.

All Enzo Biochem's financial reports are available here. More information about Enzo Biochem can be found it's website. .